ITP Education Kit

Order the ITP Education Kit for your patients
educational patient kit

Healthcare Professionals

View the New WinRho® eDetail

Learn more about this front-line1
therapy used to treat children and adults with ITP*. This short presentation is narrated by Marc Salit, Ph.D., Immunology.

*Children with acute or chronic ITP. Adults with chronic ITP.
 

View this Animation about ITP and WinRho® and download a copy to share with your patients.

WinRho® SDF Liquid4

Discover the benefits of WinRho® SDF Liquid for patients with Immune Thrombocytopenic Purpura (ITP). The liquid formulation eliminates the need for reconstitution, enhancing convenience for patients and healthcare professionals.

Incidence of ITP2

  • Estimated incidence of ITP is 100 cases per million per year
  • The Platelet Disorder Support Association (PDSA) estimates that there are approximately 200,000 people in the U.S. with ITP2

Symptoms of ITP 3

  • Spontaneous bruising (purpura): purplish areas on skin or mucous membranes
  • Petechiae: pinpoint red spots on the skin (typically the legs) that often occur in groups and may look like a rash
  • Bleeding that is hard to stop
  • Bleeding from gums
  • Nosebleeds
  • Heavy menstrual bleeding in women (menorrhagia)
  • Blood in the urine
  • Blood in the stool

Indications and Usage4

WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] is a purified human immunoglobulin used to treat immune thrombocytopenic purpura or ITP.

WinRho® SDF must be administered via the intravenous route when used in
clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomized, Rho(D) positive:

  • children with chronic or acute ITP,
  • adults with chronic ITP, or
  • children and adults with ITP secondary to HIV infection

The safety and efficacy of WinRho® have not been evaluated in clinical
trials for patients with non-ITP causes of thrombocytopenia or in previously
splenectomized patients or in patients who are Rho(D) negative.

WinRho® SDF should not be administered to:

  • Rho(D) negative patients
  • splenectomized patients
  1. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005; 106: 2244-2251.
  2. Platelet Disorder Support Association website 2007. About ITP. Available at: http://www.pdsa.org/itp-information/index.html. Accessed September 7, 2007.
  3. National Institutes of Health. National Heart, Lung and Blood Institute Diseases and Conditions Index. What Are the Signs and Symptoms of Idiopathic Thrombocytopenic Purpura? Available at http://www.nhlbi.nih.gov/health/dci/Diseases/Itp
    /ITP_SignsAndSymptoms.html    . Accessed September 14, 2007.
  4. WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation, Winnipeg, Canada. Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.